Financials
| Half-year Report | Sep. 30, 2025 |
| Final Results | Apr. 28, 2025 |
| Half-year Report | Sep. 27, 2024 |
| Final Results | Apr. 25, 2024 |
| Half-year Report | Sep. 28, 2023 |
| Final Results for the Year Ended 31 December 2022 | Apr. 28, 2023 |
| Half-year Report | Sep. 29, 2022 |
Proxies
| Result of AGM | May. 29, 2025 |
| AGM Correction | May. 13, 2025 |
| Notice of AGM | May. 02, 2025 |
| Result of Annual General Meeting | Jun. 27, 2024 |
| Posting of Annual Report & Notice of AGM | Jun. 03, 2024 |
| Result of Annual General Meeting | Jun. 30, 2023 |
| Resolutions passed at Annual General Meeting of Hemogenyx Pharmaceuticals plc on 30 June 2023 | Jun. 30, 2023 |
Ownership Update
| Holding(s) in Company | Sep. 18, 2025 |
| Director/PDMR Shareholding | May. 30, 2022 |
| Holding(s) in Company | May. 27, 2021 |
| Holding(s) in Company | May. 27, 2021 |
| Director/PDMR Shareholding | May. 19, 2021 |
| Director/PDMR Shareholding | Mar. 09, 2021 |
| Further re. Grant of Options | Sep. 22, 2020 |
Announcements
| Clinical Trial Update and Grant of Share Awards | Oct. 29, 2025 |
| Clearance to Initiate Pediatric Enrolment | Oct. 06, 2025 |
| Total Voting Rights | Sep. 30, 2025 |
| Hemogenyx Signs Letter of Intent | Sep. 23, 2025 |
| Third Patient Safety | Sep. 17, 2025 |
| Invitation to Participate at DCNY Summit | Sep. 11, 2025 |
| Manufacturing Partnership with Made Scientific | Sep. 08, 2025 |
Prospectuses
| Issue of convertible loan notes | Sep. 01, 2025 |
| Issue of convertible loan notes | Feb. 19, 2025 |
| Prospectus | Jan. 29, 2021 |
| Hemogenyx Pharmaceuticals Plc - Single prospectus | Jan. 29, 2021 |
| Financing Facility of up to £60 Million | Nov. 18, 2020 |
| Prospectus | Sep. 11, 2017 |
| Prospectus relating to the placing of 43,300,000 New Ordinary shares of £0. | Nov. 03, 2015 |